 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
We regularly sponsor clinical trials to test possible new and improved treatments for Alzheimer's disease (AD). These studies help to determine if new or currently used medications can prevent AD or slow its progression. We are currently enrolling for a new treatment study for Alzheimer's disease. The Investigational Clinical Amyloid Research in Alzheimer's (ICARA) study is investigating the effectiveness of a new study vaccine, Bapineuzumab, in slowing the progression of AD. We are participating in a new treatment study for Alzheimer’s disease. This study is testing whether a new medication called DHA is helpful in slowing the progression of AD We are participating in a second treatment study taking place at multiple centers worldwide. This treatment study is testing whether a new medication called Flurizan (tarenflurbil) is helpful in slowing the progression of AD. Our site was one of six nationwide for the NIA-funded prevention study called ADAPT. This large clinical trial examined whether certain medications, known as non-steroidal anti-inflammatory medications (NSAIDs), could prevent AD. We also participate in studies sponsored by the national Alzheimer's Disease Cooperative Study (ADCS). We are one of approximately 75 participating sites in the ADCS, which collectively conduct large-scale studies that would not be possible at any one individual site. |
|
 |
 |
 |
 |
 |
|